Top

Cancer Causes & Control

Published in:

01-02-2014 | Original Paper

Carcinogenic HPV prevalence and age-specific type distribution in 40,382 women with normal cervical cytology, ASCUS/LSIL, HSIL, or cervical cancer: what is the potential for prevention?

Authors: Susanne K. Kjær, Christian Munk, Jette Junge, Thomas Iftner

Published in: Cancer Causes & Control | Issue 2/2014

Abstract

Background

Assessment of the prevaccination type-specific prevalence of human papillomavirus (HPV) in the general population is important for the prediction of the impact of HPV vaccination.

Methods

We collected consecutively residual specimens from liquid-based cytology samples from 40,382 women from the general population in Copenhagen, Denmark, during 2002–2005. All samples were tested for high-risk HPV using the Hybrid Capture 2 technique, and genotyping was done using LiPa (Innogenetics). Through linkage with the Pathology Data Bank, we obtained information on the cytology result, and histology if any, on all women.

Results

The participants were 14–95 years of age (median age 37 years) at enrollment. The overall prevalence of HR HPV was 20.6 % ranging from 46.0 % in 20–23-year-old women to 5.7 % in women 65 years or older. Independently of cytology/histology, HPV16 was the most prevalent type. For virtually all HPV types, the occurrence of CIN3+ was higher when the specific HPV type was present together with HPV16 than it was together with other high-risk HPV types than HPV16 or if the HPV type occurred as a single infection. The prevalence of HPV16 and/or HPV18 was 74 % in cervical cancer and the corresponding prevalence of HPV16/18/31/33/45/52/58 was 89 %.

Conclusion

This study forms a valuable starting point for monitoring the effect of HPV vaccination in Denmark. In addition, the particular carcinogenic role of HPV16 and 18 is confirmed and may support a role of genotyping for HPV16 and 18 in cervical cancer screening.

Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127(12):2893–2917. doi:10.1002/ijc.25516 PubMedCrossRef

Muñoz N, Castellsagué X, de Gonzáles AB, Gissman L (2006) Chapter 1. HPV in the etiology of human cancer. Vaccine 24(Suppl 3):1–10CrossRef

NORDCAN (http://www.ancr.nu/default_old.asp) updated Oct. 2009

Noehr B, Jensen A, Frederiksen K, Tabor A, Kjaer SK (2009) Loop electrosurgical excision of the cervix and subsequent risk for spontaneous preterm delivery: a population-based study of singleton deliveries during a 9-year period. Am J Obstet Gynecol 201(1):33.e1–6. doi:10.1016/j.ajog.2009.02.004 PubMedCrossRef

Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romonowski B, Roteli-Martins CM et al (2006) Sustained efficacy up to 4–5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367:1247–1255PubMedCrossRef

Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G et al (2009) A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila) 2(10):868–878. doi:10.1158/1940-6207.CAPR-09-0031 CrossRef

Lehtinen M, Dillner J (2013) Clinical trials of human papillomavirus vaccines and beyond. Nat Rev Clin Oncol 10(7):400–410. doi:10.1038/nrclinonc.2013.84 PubMedCrossRef

Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S et al (2007) Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356(19):1928–1943PubMedCrossRef

Joura EA, Leodolter S, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA et al (2007) Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) virus-like particle vaccine against high-grade vulvar and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 369(9574):1693–1702PubMedCrossRef

10.

Nielsen A, Kjaer SK, Munk C, Iftner T (2008) Type-specific HPV infection and multiple HPV types: prevalence and risk factor profile in nearly 12,000 younger and older Danish women. Sex Transm Dis 35(3):276–282PubMedCrossRef

11.

Kjær SK, Breugelmans G, Munk C, Junge J, Watson M, Iftner T (2008) Population-based prevalence, type- and age-specific distribution of HPV in women before introduction of an HPV-vaccination program in Denmark. Int J Cancer 123(8):1864–1870PubMedCrossRef

12.

Nielsen A, Iftner T, Nørgaard M, Munk C, Junge J, Kjaer SK (2012) The importance of low-risk HPV infection for the risk of abnormal cervical cytology/histology in more than 40 000 Danish women. Sex Transm Infect 88(8):627–632. doi:10.1136/sextrans-2011-050307 PubMedCrossRef

13.

Brown DR, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM et al (2009) The impact of quadrivalent hpv (type 6/11/16/18) L1 VLP vaccine on infection and disease due to Oncogenic non-vaccine HPV types in generally HPV naive women aged 16–26. J Infect Dis 199(7):926–935PubMedCrossRef

14.

Wheeler CM, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Perez G (2009) The impact of quadrivalent HPV (types 6/11/16/18) L1 vlp vaccine on infection and disease due to oncogenic non-vaccine hpv types in sexually active women aged 16–26. J Infect Dis 199(7):936–944PubMedCrossRef

15.

Malagon T, Drolet M, Boily MC, Franco EL, Jit M, Brisson J, Brisson M (2012) Crossprotective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis 12(10):781–789PubMedCrossRef

16.

Munk C, Kjaer SK, Poll P, Bock JE (1998) Cervical cancer screening: knowledge of own screening status among women aged 20–29 years. Acta Obstet Gynecol Scand 77(9):917–922PubMedCrossRef

17.

Pedersen CB (2011) The Danish civil registration system. Scand J Public Health 39(Suppl 7):22–25PubMedCrossRef

18.

Bjerregaard B, Larsen OB (2011) The Danish pathology register. Scand J Public Health 39(Suppl 7):72–74PubMedCrossRef

19.

Bruni L, Diaz M, Castellsagué X, Ferrer E, Bosch FX, de Sanjosé S (2010) Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis 202(12):1789–1799. doi:10.1086/657321 PubMedCrossRef

20.

Jensen KE, Munk C, Sparen P, Tryggvadottir L, Liaw KL, Dasbach E, Nygård M, Kjaer SK (2011) Women’s sexual behavior. Population-based study among 65,000 women from four Nordic countries before introduction of human papillomavirus vaccination. Acta Obstet Gynecol Scand 90(5):459–467. doi:10.1111/j.1600-0412.2010.01066.x PubMedCrossRef

21.

Nielsen A, Kjaer SK, Munk C, Osler M, Iftner T (2010) Persistence of high-risk human papillomavirus infection in a population-based cohort of Danish women. J Med Virol 82(4):616–623. doi:10.1002/jmv.21750 PubMedCrossRef

22.

Winer RL, Hughes JP, Feng Q, Xi LF, Cherne S, O’Reilly S, Kiviat NB, Koutsky LA (2011) Early natural history of incident, type-specific human papillomavirus infections in newly sexually active young women. Cancer Epidemiol Biomarkers Prev 20(4):699–707PubMedCentralPubMedCrossRef

23.

Passmore JA, Morroni C, Shapiro S, Williamson AL, Hoffman M (2007) Papanicolaou smears and cervical inflammatory cytokine responses. J Inflamm (Lond) 4:8CrossRef

24.

Arbyn M, Martin-Hirsch P, Buntinx F, Van Ranst M, Paraskevaidis E, Dillner J (2009) Triage of women with equivocal or low-grade cervical cytology results: a meta-analysis of the HPV test positivity rate. J Cell Mol Med 13(4):648–659. doi:10.1111/j.1582-4934.2008.00631.x PubMedCrossRef

25.

Arbyn M, Benoy I, Simoens C, Bogers J, Beutels P, Depuydt C (2009) Prevaccination distribution of human papillomavirus types in women attending at cervical cancer screening in Belgium. Cancer Epidemiol Biomarkers Prev 18(1):321–330. doi:10.1158/1055-9965.EPI-08-0510 PubMedCrossRef

26.

Sargent A, Bailey A, Almonte M, Turner A, Thomson C, Peto J, Desai M, Mather J, Moss S, Roberts C, Kitchener HC, ARTISTIC Study Group (2008) Prevalence of type-specific HPV infection by age and grade of cervical cytology: data from the ARTISTIC trial. Br J Cancer 98(10):1704–1709. doi:10.1038/sj.bjc.6604324 PubMedCentralPubMedCrossRef

27.

Kjær SK, Frederiksen K, Munk C, Iftner T (2010) Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J Natl Cancer Inst 102(19):1478–1488. doi:10.1093/jnci/djq356 PubMedCrossRef

28.

Dillner J, Rebolj M, Birembaut P, Petry KU, Szarewski A, Munk C, de Sanjose S, Naucler P, Lloveras B, Kjaer S, Cuzick J, van Ballegooijen M, Clavel C, Iftner T (2008) Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 337:a1754PubMedCentralPubMedCrossRef

29.

Kjaer S, Høgdall E, Frederiksen K, Munk C, van den Brule A, Svare E, Meijer C, Lorincz A, Iftner T (2006) The absolute risk of cervical abnormalities in high-risk human papillomavirus-positive, cytologically normal women over a 10-year period. Cancer Res 66(21):10630–10636PubMedCrossRef

30.

Castellsagué X, Díaz M, de Sanjosé S, Muñoz N, Herrero R, Franceschi S, Peeling RW, Ashley R, Smith JS, Snijders PJ, Meijer CJ, Bosch FX, International Agency for Research on Cancer Multicenter Cervical Cancer Study Group (2006) Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst 98(5):303–315PubMedCrossRef

31.

Herrero R, Castle PE, Schiffman M, Bratti MC, Hildesheim A, Morales J et al (2005) Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica. J Infect Dis 191:1796–1807PubMedCrossRef

32.

Castle PE, Schiffman M, Wheeler CM, Wentzensen N, Gravitt PE (2010) Human papillomavirus genotypes in cervical intraepithelial neoplasia grade 3. Cancer Epidemiol Biomarkers Prev 19:1675–1681PubMedCentralPubMedCrossRef

33.

Castle PE, Shaber R, Lamere B, Kinney W, Fetterman B, Poitras N et al (2011) Human papillomavirus (HPV) genotypes in women with cervical precancer and cancer at Kaiser Permanente Northern California. Cancer Epidemiol Biomarkers Prev 20:946–953PubMedCentralPubMedCrossRef

34.

Baandrup L, Munk C, Andersen KK, Junge J, Iftner T, Kjær SK (2012) HPV16 is associated with younger age in women with cervical intraepithelial neoplasia grade 2 and 3. Gynecol Oncol 124(2):281–285. doi:10.1016/j.ygyno.2011.10.020 PubMedCrossRef

35.

Blomberg M, Dehlendorff C, Munk C, Kjaer SK (2013) Strongly decreased risk of genital warts after vaccination against human papillomavirus: nationwide follow-up of vaccinated and unvaccinated girls in Denmark. Clin Infect Dis 57(7):929–934. doi:10.1093/cid/cit436 PubMedCrossRef

Title: Carcinogenic HPV prevalence and age-specific type distribution in 40,382 women with normal cervical cytology, ASCUS/LSIL, HSIL, or cervical cancer: what is the potential for prevention?
Authors: Susanne K. Kjær
Christian Munk
Jette Junge
Thomas Iftner
Publication date: 01-02-2014
Publisher: Springer International Publishing
Published in: Cancer Causes & Control / Issue 2/2014
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI: https://doi.org/10.1007/s10552-013-0320-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2014

The association of vitamin D supplementation with the risk of cancer in postmenopausal women

Distance from residence to power line and risk of childhood leukemia: a population-based case–control study in Denmark

A meta-analysis of the association between induced abortion and breast cancer risk among Chinese females

Parity and breastfeeding among African-American women: differential effects on breast cancer risk by estrogen receptor status in the Women’s Circle of Health Study

Changes in colorectal cancer incidence rates in young and older adults in the United States: what does it tell us about screening

Association between statin use and colorectal cancer risk: a meta-analysis of 42 studies

Keynote webinar | Spotlight on antibody–drug conjugates in cancer